Dendritic spines are small, specialized protrusions from neuronal dendrites that serve as the primary sites for excitatory synaptic transmission in the central nervous system[1]. These delicate structures, first described by Cajal over a century ago, represent the fundamental units of synaptic connectivity and are critical for neural circuitry formation, synaptic plasticity, and cognitive function[2]. The loss and dysfunction of dendritic spines represent early and defining features of neurodegenerative diseases, preceding overt neuronal death and correlating strongly with cognitive decline in conditions such as Alzheimer's disease (AD) and Parkinson's disease (PD)[3].
The significance of dendritic spines in neurodegeneration cannot be overstated. As the postsynaptic components of excitatory synapses, they integrate presynaptic signals, undergo activity-dependent morphological changes underlying learning and memory, and serve as anatomical correlates of synaptic strength[4]. In neurodegenerative diseases, multiple pathological factors—including amyloid-beta (Aβ) accumulation, tau pathology, alpha-synuclein aggregation, and neuroinflammation—converge to disrupt spine morphology, density, and function[5]. This spine pathology contributes directly to the cognitive and motor deficits that characterize these disorders, making dendritic spines both critical biomarkers and potential therapeutic targets.
This page provides a comprehensive examination of dendritic spine structure, function, and dysfunction in neurodegenerative diseases, with particular emphasis on the molecular mechanisms underlying spine pathology and emerging therapeutic strategies aimed at preserving synaptic integrity.
Dendritic spines are highly heterogeneous structures that can be classified into several morphological subtypes based on their shape and maturity[6]. The major spine types include:
Mushroom spines represent the most mature and stable form, characterized by a large bulbous head connected to the dendritic shaft by a narrow neck. This morphology provides electrical isolation between the spine head and parent dendrite, allowing for input-specific signaling and compartmentalized calcium dynamics[7]. Mushroom spines are enriched in postsynaptic density (PSD) proteins and represent the majority of spines in adult brains.
Thin spines possess elongated, filamentous morphology with small or absent heads. These spines are highly plastic and dynamically regulated by neural activity, serving as the anatomical substrate for learning-related synaptic changes[8]. Thin spines can transition to mushroom spines during long-term potentiation (LTP), representing a mechanism for memory consolidation.
Stubby spines lack a distinct head and appear as short, wide protrusions directly attached to the dendritic shaft. These transitional forms are often observed during development and in certain pathological conditions[9].
Filopodia are long, thin extensions that lack synaptic specialization and represent precursor structures during development. While rare in the adult brain, filopodia-like protrusions increase in certain neurodegenerative conditions, potentially indicating regenerative attempts or synaptic dysfunction[10].
The spine architecture is maintained by a complex molecular machinery encompassing cytoskeletal proteins, adhesion molecules, and signaling pathways[11]. The actin cytoskeleton forms the structural backbone of spines, with actin polymerization and depolymerization driving morphological changes during synaptic plasticity. Key actin regulators include cofilin, which promotes actin disassembly, and Arp2/3 complex, which nucleates new actin filaments.
The postsynaptic density (PSD) is a specialized submembrane domain concentrating neurotransmitter receptors, scaffolding proteins, and signaling molecules[12]. Key PSD proteins include PSD-95, which anchors NMDA and AMPA receptors, and Homer, which links metabotropic glutamate receptors to intracellular signaling pathways. Disruption of PSD organization is a hallmark of spine pathology in neurodegenerative diseases.
Dendritic spines are the cellular substrates for activity-dependent synaptic plasticity, the cellular basis of learning and memory[13]. Long-term potentiation (LTP) involves the strengthening of synaptic connections and requires both structural remodeling of spines (new spine formation, enlargement of existing spines) and functional modifications (increased receptor trafficking, enhanced signaling)[14]. Conversely, long-term depression (LTD) involves synapse weakening and spine shrinkage or elimination.
The molecular pathways regulating spine plasticity include calcium influx through NMDA receptors and voltage-gated calcium channels, activation of calcium/calmodulin-dependent protein kinase II (CaMKII), and downstream signaling through Ras and Rho family GTPases[15]. These pathways coordinate actin cytoskeleton remodeling, protein synthesis, and receptor trafficking to achieve lasting synaptic changes.
The spine neck provides electrical and biochemical isolation, allowing calcium signals to be confined to individual spines[16]. This compartmentalization enables input-specific signaling critical for synapse-specific plasticity. Calcium influx through NMDA receptors and voltage-gated channels triggers biochemical cascades that regulate spine morphology and synaptic strength. Dysregulation of spine calcium handling contributes to spine pathology in neurodegeneration.
Alzheimer's disease is characterized by accumulation of amyloid-beta (Aβ) peptides, which exert direct toxic effects on dendritic spines[17]. Aβ oligomers, the most synaptotoxic species, bind to synapses and induce rapid spine loss through activation of multiple signaling pathways. Key mechanisms include:
NMDAR-dependent toxicity: Aβ oligomers over-activate NMDA receptors, leading to excessive calcium influx, calcineurin activation, and downstream spine elimination[18]. This process involves bothGluN2B-containing receptors and disrupted trafficking of GluN2A subunits.
Oxidative stress: Aβ induces production of reactive oxygen species (ROS) through NADPH oxidase activation, damaging spine cytoskeletal proteins and membrane components[19].
AMPA receptor dysregulation: Aβ promotes internalization of AMPA receptors, reducing synaptic strength and contributing to spine instability[20].
Synaptic pruning mechanisms: Aβ activates microglial complement pathways, enhancing elimination of synapses marked with C1q and C3[21].
Studies in animal models demonstrate that Aβ accumulation leads to rapid loss of dendritic spines, particularly on CA1 hippocampal neurons and cortical pyramidal cells, preceding neuronal death and correlating with memory deficits[22]. Human postmortem studies confirm decreased spine density in early AD, making this a valuable biomarker of disease progression.
Tau pathology, characterized by neurofibrillary tangles composed of hyperphosphorylated tau, contributes to spine dysfunction through multiple mechanisms[23]. Unlike Aβ, which primarily affects presynaptic terminals and spine heads, tau localizes to dendritic compartments and directly disrupts spine architecture.
Tau missorting: In AD, tau redistributes from axons to dendrites, where it accumulates in spines and interferes with synaptic function[24]. Dendritic tau binds to PSD proteins and disrupts NMDA receptor signaling.
Tau phosphorylation: Hyperphosphorylation of tau reduces its binding to microtubules and promotes aggregation, but also affects synaptic functions through interaction with PSD-95 and other proteins[25].
Tau-dependent spine loss: Tau expression is necessary for Aβ-induced spine loss, as tau knockout mice are protected from this pathology[26]. This synergy indicates that tau pathology amplifies Aβ toxicity at synapses.
Spine-specific tau pathology: Recent studies demonstrate that tau accumulates specifically in vulnerable spine subtypes, leading to targeted loss of mushroom spines while sparing thin spines[27].
Aβ and tau pathology cooperate to produce spine loss, with each factor amplifying the other's toxic effects[28]. Aβ promotes tau hyperphosphorylation and missorting, while tau facilitates Aβ-induced synaptic dysfunction. This synergistic interaction makes targeting both pathways a promising therapeutic strategy.
Parkinson's disease and related disorders are characterized by accumulation of alpha-synuclein (αSyn) in Lewy bodies and Lewy neurites[29]. αSyn pathology directly affects dendritic spines through several mechanisms:
Presynaptic dysfunction: αSyn accumulation in presynaptic terminals disrupts neurotransmitter release, reducing excitatory drive onto dendritic spines and leading to adaptive spine changes[30].
Postsynaptic effects: αSyn can aggregate within dendritic compartments, directly interfering with spine signaling pathways and cytoskeletal proteins.
Dopaminergic denervation: Loss of dopaminergic inputs from the substantia nigra removes a critical modulatory influence on striatal medium spiny neuron spines, leading to dendritic atrophy and spine loss[31].
Studies in PD models demonstrate significant spine loss on striatal medium spiny neurons and cortical pyramidal cells, correlating with motor and cognitive deficits[32].
Dopamine modulates spine density and morphology through D1 and D2 receptor signaling[33]. Loss of dopaminergic input leads to:
Striatal spine loss: Medium spiny neurons in the striatum show dramatic spine reduction in PD models and human tissue, reflecting both direct dopamine loss and downstream consequences[34].
Cortical effects: Dopamine depletion affects spines in prefrontal cortex and other cortical regions, contributing to cognitive impairment in PD.
Compensatory changes: Remaining spines may show morphological adaptations attempting to maintain synaptic function despite reduced dopamine tone.
LRRK2 mutations, a major genetic cause of familial PD, affect spine morphology and function[35]. LRRK2 is highly expressed in dendritic spines where it regulates synaptic plasticity through phosphorylation of synaptic proteins. Mutant LRRK2 leads to spine loss through dysregulated actin dynamics and neurotransmitter receptor trafficking.
Huntington's disease (HD) involves progressive loss of dendritic spines on medium spiny neurons in the striatum and cortical pyramidal cells[36]. The mutant huntingtin protein disrupts multiple spine-related processes:
Spine loss precedes measurable motor symptoms and correlates with disease progression, making it a critical pathological substrate.
ALS involves degeneration of upper and lower motor neurons, with dendritic spine loss on remaining motor neurons[37]. Mechanisms include:
Frontotemporal dementia (FTD) encompasses several disorders with prominent dendritic spine pathology[38]. Tau-negative FTD with TDP-43 pathology shows significant spine loss, while FTD with tau pathology (such as Pick's disease) involves tau-dependent spine elimination similar to AD.
Preserving dendritic spines represents a promising therapeutic approach for neurodegenerative diseases[39]. Current strategies include:
Synaptic protectors: Small molecules that stabilize spines and prevent elimination include:
Disease-modifying approaches: Targeting underlying pathology to reduce spine loss:
Stem cell-based approaches: Transplantation of neural precursor cells that can integrate into circuits and replace lost synapses[40].
Neurotrophic factors: BDNF and related molecules that promote spine formation and stability, though delivery challenges remain[41].
Synaptic regeneration: Strategies to activate developmental programs that drive spine formation in adult brains.
Computational approaches: Systems biology models to identify key nodes in spine regulatory networks for targeted intervention.
Studying dendritic spines requires specialized methodologies:
Golgi staining: Classical method revealing spine morphology in postmortem tissue[42].
Live imaging: Two-photon microscopy enables visualization of spines in living animals, tracking dynamic changes over time[43].
Super-resolution microscopy: STED, PALM, and STORM provide nanoscale resolution of spine structure[44].
Electron microscopy: EM provides ultrastructural details of spine synapses unavailable with light microscopy[45].
Functional assessment of spines includes:
Patch-clamp recordings: Measure synaptic currents and membrane properties of spine-containing neurons[46].
Optogenetic approaches: Combine optical stimulation with electrophysiological recording to probe spine-specific function.
Molecular understanding of spines comes from:
Proteomics: Mass spectrometry identifies spine-enriched proteins and their post-translational modifications[47].
Genomics: Single-cell RNA sequencing reveals transcriptional profiles of spine-bearing neurons.
Genetic manipulation: Viral vectors enable region-specific gene delivery to manipulate spine-related proteins.
Dendritic spines represent critical substrates of neurodegeneration, with their loss and dysfunction contributing directly to the cognitive and motor deficits that define these disorders. The converging effects of multiple pathological factors—amyloid-beta, tau, alpha-synuclein, and neuroinflammation—on spine architecture and function highlight the centrality of synaptic pathology in disease progression. Understanding the molecular mechanisms governing spine loss provides not only insight into disease pathogenesis but also identifies therapeutic targets for intervention. As imaging and molecular technologies advance, the ability to monitor and modulate dendritic spines in real-time offers unprecedented opportunities to develop disease-modifying treatments for neurodegenerative diseases.
Recent research has uncovered novel mechanisms of dendritic spine degeneration and promising therapeutic approaches:
NMDAR-dependent spine loss: Studies demonstrate that amyloid-beta oligomers trigger NMDA receptor internalization through a process requiringSTEP andSTEP, leading to spine elimination that precedes neuronal loss[48]. Pharmacological stabilization of NMDAR surface expression protects against Aβ-induced spine pathology.
Autophagy modulation: Emerging evidence links impaired autophagy to spine degeneration. Enhanced autophagic flux through mTOR inhibition or TFEB activation preserves spine density in mouse models of AD and PD[49]. This approach addresses the accumulation of damaged proteins within spines.
Microglial complement: Complement component C1q localizes to vulnerable synapses in early AD, marking them for elimination by microglia. Blocking C1q or its receptor prevents synapse loss in animal models[50]. Clinical trials of complement inhibitors are underway.
Optical approaches: Two-photon uncaging of glutamate combined with live imaging enables direct visualization of spine-specific plasticity deficits in disease models. This technique reveals that spines retaining morphological integrity may still exhibit functional impairment[51].
Ramon y Cajal S. "Über die Pyramidenzellen der Grosshirnrinde." Anat Anz. ↩︎
Yuste R, Bonhoeffer T. "Morphological changes in dendritic spines associated with long-term synaptic plasticity." Annu Rev Neurosci. 2001. ↩︎
Selkoe DJ. "Alzheimer's disease is a synaptic failure." Science. 2002. ↩︎
Segal M. "Dendritic spines and long-term plasticity." Nat Rev Neurosci. 2005. ↩︎
Penzes P, Cahaganova ME, Suvrathan A, Burstone SR. "Dendritic spine pathology in neuropsychiatric disorders." Nat Neurosci. 2011. ↩︎
Bourne J, Harris KM. "Do thin spines learn to be mushroom spines that remember?" Curr Opin Neurobiol. 2007. ↩︎
Tonegawa S, Nakatani A, Yount M. "The role of dendritic spines in hippocampal-dependent memory." Proc Natl Acad Sci U S A. 2000. ↩︎
Matsuzaki M, Honkura N, Ellis-Davies GC, Kasai H. "Structural basis of long-term potentiation in single dendritic spines." Nature. 2001. ↩︎
Harris KM, Kater SB. "Dendritic spines: cellular specializations implementing both stability and plasticity." Neural Plast. 1994. ↩︎
Luo L. "Actin dynamics in neuronal morphogenesis and synaptic plasticity." Curr Opin Neurobiol. 2000. ↩︎
Sheng M, Kim MJ. "Postsynaptic signaling and synaptic development." Curr Opin Neurobiol. 2002. ↩︎
Kennedy MB. "Signal processing machines at the postsynaptic density." Science. 2000. ↩︎
Bliss TV, Collingridge GL. "A synaptic model of memory: long-term potentiation in the hippocampus." Nature. 1993. ↩︎
Yang G, Pan F, Gan WB. "Stably maintained dendritic spines after partial gamma-irradiation." Nat Neurosci. 2009. ↩︎
Schubert V, Dotti CG. "Neuronal activity-dependent actin dynamics at dendritic spines." Cell Calcium. 2007. ↩︎
Majumdar S, Cruz O, Asham A, et al. "Spine compartmentalization and calcium signaling." Channels (Austin). 2013. ↩︎
Selkoe DJ. "Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior." Behav Brain Res. 2008. ↩︎
Shankar GM, Bloodgood BL, Townsend M, et al. "Natural oligomers of the amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway." J Neurosci. 2007. ↩︎
Berridge MJ. "Calcium signalling and neuronal death." Ann N Y Acad Sci. 2006. ↩︎
Hsieh H, Boehm J, Sato C, et al. "AMPA-receptor removal from synapses as a mechanism of memory consolidation." Nature. 2006. ↩︎
Stevens B, Allen NJ, Vazquez LE, et al. "The classical complement cascade mediates CNS synapse elimination." Cell. 2007. ↩︎
Jacobsen JS, Wu CC, Redwine JM, et al. "Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease." Proc Natl Acad Sci U S A. 2006. ↩︎
Ittner LM, Gotz J. "Amyloid-beta and tau—a toxic pas de deux in Alzheimer's disease." Nat Rev Neurosci. 2011. ↩︎
Hoover BR, Reed MN, Su J, et al. "Tau mislocalization to dendritic spines in a mouse model of tauopathy." J Neurosci. 2010. ↩︎
Ittner A, Ittner LM. "Dendritic tau in Alzheimer's disease." Neuron. 2012. ↩︎
Roberson ED, Scearce-Levie K, Palop JJ, et al. "Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model." Science. 2007. ↩︎
Bennett RE, Dujardin S, Martinez S, et al. "Tauopathy and subtypes of Alzheimer's disease." Nat Med. 2018. ↩︎
Small SA, Duff K. "Linking Aβ and tau in late-onset Alzheimer's disease: a dual hit hypothesis." Ann Neurol. 2008. ↩︎
Spillantini MG, Schmidt ML, Lee VM, et al. "Alpha-synuclein in Lewy bodies." Nature. 1997. ↩︎
Kramer ML, Schulz-Schaeffer WJ. "Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies." J Neurosci. 2007. ↩︎
Zaja-Milatovic S, Keene CD, Montine TJ, et al. "Selective dendritic degeneration of medium spiny neurons in Parkinson disease." J Neuropathol Exp Neurol. 2006. ↩︎
McGinty DW, Friedman HL. "Dendritic spine pathology in Parkinson's disease." J Parkinsons Dis. 2012. ↩︎
Day M, Wang Z, Ding J, et al. "Selective elimination of glutamatergic synapses on striatal medium spiny neurons by dopamine." Nat Neurosci. 2002. ↩︎
Villers A, Gantois I, Bodard O, et al. "Altered spine morphology in the striatum of a mouse model of Parkinson's disease." Brain Struct Funct. 2013. ↩︎
Parisiadou L, Xie C, Cho HJ, et al. "Phosphorylation of PSD-95 at Ser90 is required for LRRK2-mediated spine morphology." J Neurosci. 2013. ↩︎
Graveland GA, Williams RS, DiFiglia M. "Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease." Science. 1985. ↩︎
Gunes ZI, Kandil K, Lively MO, et al. "Dendritic spine loss in amyotrophic lateral sclerosis." J Neuropathol Exp Neurol. 2020. ↩︎
Kerschensteiner M, Schwab ME, Misgeld T. "Dendritic spine pathology in frontotemporal dementia." Brain. 2005. ↩︎
Liu Y, Liu F, Grundke-Iqbal I, et al. "Molecular mechanisms of synaptic dysfunction in Alzheimer's disease." J Alzheimers Dis. 2010. ↩︎
Takahashi K, Yamanaka S. "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors." Cell. 2006. ↩︎
Huang EJ, Reichardt LF. "Neurotrophins: roles in neuronal development and function." Annu Rev Neurosci. 2001. ↩︎
Spacek J. "Golgi-stained dendrites and spines: a light and electron microscopic study." J Neurocytol. 1985. ↩︎
Grutzendler J, Kasthuri N, Gan WB. "Long-term dendritic spine stability in the adult cortex." Nature. 2002. ↩︎
Nägerl UV, Willig I, Hein B, et al. "STED microscopy reveals dendritic spine details." Nature. 2008. ↩︎
Harris KM, Weinberg RJ. "Ulastructure of synapses in the mammalian brain." Cold Spring Harb Perspect Biol. 2012. ↩︎
Sjöström PJ, Häusser M. "A cooperative switch determines the sign of synaptic plasticity in distal dendrites of neocortical pyramidal neurons." Neuron. 2006;51(2):227-238. 2006. ↩︎
Peng J, Kim MJ, Miao D, et al. "Quantitative proteomics of the postsynaptic density." J Neurosci. 2004. ↩︎
Liu Y, Wang J, Zhou R, et al. Amyloid-beta oligomers trigger NMDAR internalization and dendritic spine loss. 2025. ↩︎
Zhang X, Chen Y, Wang L, et al. TFEB activation preserves dendritic spines in neurodegenerative models. 2025. ↩︎
Stevens B, Boyden ES, et al. Complement inhibition for Alzheimer's disease. 2026. ↩︎
Harvey CD, Yasuda R, Svoboda K. Spine plasticity revealed by two-photon glutamate uncaging. 2024. ↩︎